



# SyrSpend<sup>®</sup> SF PH4 NEO

Safe for those who need you the most

# SyrSpend® SF PH4 NEO

Safe for those who need you the most

Taking care of your most vulnerable patients in the best possible way: discover SyrSpend® SF PH4 NEO.

## Dosing challenges in treating pediatric patients

The statement that children are not small adults is valid particularly valid in pediatric clinical care.<sup>1</sup> Infancy and childhood mark a period of rapid growth and development.

Physiology of neonates and infants differs considerably from that of adults; they may not be able to metabolize or eliminate active substances and excipients in pharmaceutical products in the same manner.

Absorption, distribution, metabolism and excretion vary significantly during development, with most pronounced changes during the first year of life.<sup>2</sup>

When it comes to excretion, neither hepatic clearance nor glomerular or filtration tubular secretion are mature at birth and development to adult capacity may take up to 12 months.<sup>2</sup>

The wide age range of children treated in clinical settings result in doses that can vary 50-fold through childhood.<sup>3</sup>

For a medicinal product to be used in all age groups, a range of different dosage forms should be available providing different strengths or concentrations to allow simple, accurate and safe dosing.<sup>2,4</sup>

The use of liquid formulations is encouraged as it provides maximal dosing flexibility and allows the use of a single formulation over different ages.<sup>2,3</sup>

As not all liquid formulations are commercially available, there is a broad range of drugs that need to be compounded by the pharmacist.

## Avoidable excipients in pediatric patients

Excipients should be pharmacologically inactive, but may cause adverse events in daily practice. Particularly neonates and infants are not always able to metabolize or eliminate an ingredient in a pharmaceutical product in the same manner as an adult.<sup>2</sup>

Excipients that need to be avoided in neonates and infants include ethanol, propylene glycol, polyethylene glycol, benzyl alcohol, parabens, benzoic acid, sucrose, fructose, mannitol, sorbitol, xylitol, aspartame, and colorings.<sup>5</sup> Cumulative exposure can increase excipient toxicity.<sup>5-6</sup>

# SyrSpend® SF PH4 NEO

Safe for those who need you the most

## The solution: SyrSpend® SF PH4 NEO

The latest addition to the successful line of Fagron's oral vehicle bases is SyrSpend® SF PH4 NEO, which inherited the patented *Active Suspending Technology* to maximize dosing safety.<sup>7,8</sup>

In addition, SyrSpend® SF PH4 NEO is free of sugar, sorbitol, colorants, parabens or any other harmful or controversial ingredients. SyrSpend® SF PH4 NEO is preserved with 0.2% Sorbic acid, which makes it suitable for all patient groups.<sup>9-12</sup>

SyrSpend® SF PH4 NEO is quick and easy to compound with and provides pharmaceutical stability and dosage consistency with each preparation. The use of starch means that SyrSpend® SF PH4 NEO is compatible with a broad range of APIs. All combinations are included in the SyrSpend® SF PH4 NEO compatibility table and Compounding Matters formulations database.

## SyrSpend® SF PH4 NEO example formulations

Acetaminophen 50 mg/mL

Phenobarbital 9 mg/mL

Caffeine 10 mg/mL

Ranitidine 14 mg/mL

Midazolam 1 mg/mL

Vancomycin 25 mg/mL



## References

1. Fernandez E, et al., Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults. *Pharmaceutics*. 2011;3(1):53-72.
2. [https://www.ema.europa.eu/documents/scientific-guideline/reflection-paper-formulations-choice-paediatric-population\\_en.pdf](https://www.ema.europa.eu/documents/scientific-guideline/reflection-paper-formulations-choice-paediatric-population_en.pdf)
3. Batchelor HK, Marriott JF. Formulations for children: Problems and solutions. *Br J Clin Pharmacol* 2015; 79(3): 405–418.
4. Nunn T, Williams J. Formulation of medicines for children. *Br J Clin Pharmacol* 2005;59:674–6.
5. Whittaker A, Currie AE, Turner MA, et al Toxic additives in medication for preterm infants *Archives of Disease in Childhood - Fetal and Neonatal Edition* 2009;94:F236-F240.
6. Valeur KS, Holst H, Allegaert K. Excipients in Neonatal Medicinal Products: Never Prescribed, Commonly Administered. *Pharmaceut Med*. 2018;32(4):251-258.
7. Dijkers, E, Nanhekhan V, Thorissen V and Hudson P. Suspensions as a Valuable Alternative to Extemporaneously Compounded Capsules. *International journal of pharmaceutical compounding* 21 2 (2017): 171-175.
8. Dijkers ECF, Polonini H and Ferreira A. Content Uniformity of Extemporaneous Compounded Suspensions. Abstract accepted for the EAHP 2020 congress Hospital Pharmacy 5.0 - the future of patient care.
9. Handbook of Pharmaceutical Excipients. SIXTH EDITION. Edited by. Raymond C Rowe
10. <https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/default.htm>. Accessed December 2018.
11. *Practical Pharmaceutics*. Edited by Bouwman Y., Fenton-May V. and Le Brun P. 2015
12. Personal communication with Prof. Tuleu. Professor in Paediatric Pharmaceutics, UCL School of Pharmacy, London, UK.

## Fagron BV

Lichtenauerlaan 182  
3062 ME Rotterdam  
The Netherlands

T +31 88 33 11 288  
F +31 88 33 11 210  
[www.fagron.com](http://www.fagron.com)

